July 26, 2017 1:40 PM ET

Healthcare Providers and Services

Company Overview of Spotlight Innovation Inc.

Company Overview

Spotlight Innovation Inc., a pharmaceutical company, focuses on acquiring rights to innovative and proprietary therapeutics designed to address unmet medical needs. The company is developing Crotoxin, which is in Phase I clinical study for the treatment of cancer. It also develops various compounds for the treatment of viral infections, including Zika virus infection; STL-182, an orally-available small molecule for the treatment of spinal muscular atrophy; and products derived from cobra and venom to treat chronic pain. The company, through its strategic investment in Solx, Inc., offers SOLX Gold Shunt, an implantable drainage device designed to reduce elevated intraocular pressure associate...

Building 3

11147 Aurora Avenue

Aurora Business Park

Urbandale, IA 50322

United States

2 Employees



Key Executives for Spotlight Innovation Inc.

Chairman of the Board, Interim Chief Executive Officer, President and Chief Operating Officer
Age: 58
Chief Financial Officer
Age: 62
Total Annual Compensation: $70.0K
Age: 44
Total Annual Compensation: $159.9K
Compensation as of Fiscal Year 2016.

Spotlight Innovation Inc. Key Developments

Spotlight Innovation Inc. Enters into Sponsored Research Agreement with The Brigham and Women's Hospital Inc

On June 21, 2017, Spotlight Innovation Inc. entered into a Sponsored Research Agreement with The Brigham and Women's Hospital Inc. to support research directed by BWH professor Kevin Hodgetts aimed at developing safe and effective drugs to treat patients with spinal muscular atrophy. The Company will provide to BWH an aggregate of $200,000 in funding support for the research project. The Company shall sponsor BWH's research project for a period of one year, unless sooner terminated by either party upon forty-five days advance written notice pursuant to the terms of the Agreement.

Spotlight Innovation Inc. Announces Management Changes

Spotlight Innovation Inc. announced that the company's Board of Directors has accepted the resignation of Cristopher Grunewald as Chief Executive Officer (CEO) and appointed John M. Krohn as interim CEO, effective immediately. Krohn will continue to serve as Chairman of the Board, President and Chief Operating Officer. Krohn joined the company's Board of Directors in February 2016. He has over three decades of operating and leadership experience across diverse industry sectors.

Spotlight Innovation Inc. announced delayed 10-Q filing

On 05/15/2017, Spotlight Innovation Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Similar Private Companies By Industry

Company Name Region
@ Home Medical, Inc. United States
@home approach, llc United States
@Home Care United States
1011 E. Pecan Grove Road, LLC United States
1104 Welsh Road Operations LLC United States

Recent Private Companies Transactions

Private Placement
May 31, 2017
Private Placement
December 30, 2016
Private Placement
December 16, 2016

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Spotlight Innovation Inc., please visit www.spotlightinnovation.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.